14
Participants
Start Date
July 31, 2018
Primary Completion Date
August 22, 2022
Study Completion Date
December 31, 2022
ABI-009
For dose finding, ABI-009 will start at 5 mg/m2/dose IV, once a week for three weeks, in cohorts of 3 participants each using the standard 3+3 dose-finding design
Seattle Children's Hospital, Seattle
Collaborators (1)
Aadi Bioscience, Inc.
INDUSTRY
Seattle Children's Hospital
OTHER